TPG Biotech has now invest almost $28m in the skin disorder specialist, which will use the cash to advance clinical trials for its lead product.

The company completes its license agreement with Texas and hires Mark Standeford.

It is one of the largest series A yet for a Cambridge spin-out.

The UCLA biopharmaceutical company has filed its S-1.

Covacsis, creator of a data analytics product for factory owners, has added to its series A funding with an undisclosed amount from the corporate investors.

Aver, the creator of a platform to simplify healthcare payments, has now raised about $11m from investors including GE Ventures.

The electronic equipment maker will target agricultural and life sciences companies in the US and Japan.

The company, which is developing technology to boost the effectiveness of medicine, has now raised more than $250m and has several corporates among its investors.

Numerous private investors from the City of London back Oxford spin-out's move into the ophthalmology market with $33.5m.